Home › Endometrial Cancer › NCT07643012
Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer
Recruiting
Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer: A Phase I/II Feasibility Study
Who can join
Ages 18 to 90 · Women
Full eligibility criteria
Inclusion Criteria: 1. Histologically confirmed endometrial carcinoma (endometrioid, serous, clear cell, carcinosarcoma, or dedifferentiated histology). 2. Indication for adjuvant pelvic radiotherapy (± vaginal brachytherapy) for HIR defined by the ASTRO guidelines and GOG-99(7, 9) : 3. Age 4. High-grade histology (grade 2-3) 5. Depth of myometrial invasion 6. LVSI 7. Positive pelvic nodes 8. Cervical stromal invasion 9. Presence of poor prognostic molecular markers 10. Age ≥18 years. 11. Ability to provide informed consent. 12. Eligible to receive adjuvant systemic therapy, if indicated, with a minimum 3-week interval between chemotherapy and radiotherapy. 13. Willing and able to complete EORTC QLQ-C30 and EN-24 questionnaires in a validated language version. Exclusion Criteria: 1. Prior pelvic radiotherapy. 2. Contraindication to pelvic radiotherapy (e.g., active connective tissue disorder or inflammatory bowel disease). 3. Presence of a hip prosthesis that would compromise treatment planning or delivery. \-
About the study
To evaluate the safety, tolerability, and preliminary efficacy of moderately hypofractionated (15-fraction) MR-guided adaptive pelvic IMRT in patients with endometrial cancer.
What is being tested
- MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT) (radiation)
Sponsor: Rutgers, The State University of New Jersey · Participants: 30 · Started: Jun 9, 2026
Contact the study team
- Lara Hathout, MD · Phone: 732-235-2465
Official record on ClinicalTrials.gov — NCT07643012
Locations in the U.S.
| New Jersey | Rutgers Cancer Institut Jersey, New Brunswick |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.